VolitionRX (VNRX)
:VNRX
Want to see VNRX full AI Analyst Report?
VNRX Stock Chart & Stats
$0.18
$0.01(1.52%)
At close: 4:00 PM EST
$0.18
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$1.91 - $18.78
Previous CloseN/A
Volume29.92K
Average Volume (3M)19.46M
Market Cap
$16.66M
Enterprise Value$20.79M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$11.70M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.25
Shares Outstanding8,330,270
10 Day Avg. Volume55,156,196
30 Day Avg. Volume19,458,360
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.80
Price to Sales (P/S)15.80
P/FCF Ratio-1.38
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue8.43
Enterprise Value/Gross Profit9.40
Enterprise Value/Ebitda-1.05
Forecast
1Y Price Target
$22.00Price Target Upside12122.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$6.77M
Bulls Say, Bears Say
Bulls Say
Biomarker SpecificityTargeting cancer-specific DNA regions bound by the CTCF protein could enable more tissue-specific cancer detection, supporting development of multi-cancer early screening and treatment monitoring applications.
Innovative Detection MethodCapture-Seq's enrichment approach that isolates circulating tumor DNA offers a technical advantage that may improve detection accuracy over existing liquid biopsy methods and attract partner interest.
Licensing PartnershipsOngoing discussions with multiple diagnostic and liquid biopsy companies could lead to licensing deals that provide new revenue streams and accelerate commercial adoption.
Bears Say
Capital NeedsRequirement for additional capital to fund operations increases the risk of dilution or financing strain that could pressure the stock if funding terms are unfavorable.
Financial PerformanceRevenue missed projections and net loss was larger than expected, highlighting near-term operating challenges that may weigh on investor confidence and valuation.
Share Dilution ConcernsAnalyst's price target was lowered mainly due to increased share count, signaling dilution concerns that can reduce per-share value and temper investor enthusiasm.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $1.91 and its highest was $18.78 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $16.66M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Aug 19, 2026 which is in 92 days.
How were VolitionRX’s earnings last quarter?
Currently, no data Available
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.69.
How many shares outstanding does VolitionRX have?
VolitionRX has 8,330,270 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial scientific and commercial progress across multiple product pillars (Nu.Q Vet automation and feline assay, Nu.Q NETs publications and point-of-care finger-prick breakthrough, Capture-Seq >99% pure ctDNA claims, Nu.Q Discover expansion), alongside improving headline revenue (+300% YoY) and a stronger quarter-end cash balance driven by financing and grants. However, important caveats include revenue lumpiness driven in part by deferred recognition, rising operating expenses and cash burn, reliance on milestone payments and external financing, and the need for broader validation, publications, and regulatory/reimbursement approvals to convert technical advances into predictable commercial revenue. On balance, the call signals strong technical momentum and growing commercial interest but with execution and timing risks to monetize those advances in the near term.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$22.00
▲(12122.22% Upside)
Technical Analysis
Ownership Overview
9.74% Insiders
1.15% Mutual Funds
― Other Institutional Investors
88.47% Public Companies and
Individual Investors